Market closed
Renovaro/$RENB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Renovaro
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Ticker
$RENB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
Website
Renovaro Metrics
BasicAdvanced
$60M
-
-$0.82
0.41
-
Price and volume
Market cap
$60M
Beta
0.41
52-week high
$2.34
52-week low
$0.32
Average daily volume
754K
Financial strength
Current ratio
0.06
Quick ratio
0.015
Long term debt to equity
0.822
Total debt to equity
8.755
Interest coverage (TTM)
-27.05%
Management effectiveness
Return on assets (TTM)
-18.09%
Return on equity (TTM)
-188.47%
Valuation
Price to book
0.74
Price to tangible book (TTM)
-2.33
Price to free cash flow (TTM)
-5.572
Growth
Earnings per share change (TTM)
21.95%
3-year earnings per share growth (CAGR)
2.28%
Renovaro Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Renovaro News
AllArticlesVideos
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
GlobeNewsWire·5 days ago
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
GlobeNewsWire·3 weeks ago
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Renovaro stock?
Renovaro (RENB) has a market cap of $60M as of April 27, 2025.
What is the P/E ratio for Renovaro stock?
The price to earnings (P/E) ratio for Renovaro (RENB) stock is 0 as of April 27, 2025.
Does Renovaro stock pay dividends?
No, Renovaro (RENB) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Renovaro dividend payment date?
Renovaro (RENB) stock does not pay dividends to its shareholders.
What is the beta indicator for Renovaro?
Renovaro (RENB) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.